CSI Market
Sign In | Register

Nektar Therapeutics (NKTR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NKTR Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Nektar Therapeutics adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-85.53
Depreciation & amortization0.31
Amortization of Other Assets-5.23
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use1.37
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation6.72
Income (Loss) from Equity Method Investments-2.07
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Non Cash Royalty Revenue Related To Sale Of Future Royalties-10.86
Noncash Interest Expense-
Loss From Redemption Premium And Incremental Interest On Secured Debt-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Accrued Clinical Trial Expenses-
Impairment Of Equipment From Terminated Program-
Accretion Of Discount Net And Other Non Cash Transactions-
Provision For Inventory Obsolescence-
Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities-2.41
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable14.12
Increase (Decrease) in Other Accrued Liabilities0.04
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital39.88
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-89.68
Discontinued operations0.00
Net Cash flow from Operating Activities-120.07
Investing Activities
Capital Expenditures-0.11
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities237.92
Payments to Acquire Available-for-sale Securities, Debt-987.71
Real Estate Investments0.00
Advance Payments For Property And Equipment-
Payment For Transaction Costs For Sale Of Pulmonary Assets-
Proceeds From Sale Of The Huntsville Manufacturing Facility Net-
Payment Of Transaction Costs And Working Capital Adjustment From The Sale Of Manufacturing Facility-
Proceeds From Payments For Sale Of Huntsville Manufacturing Facility Net-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-749.90
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.69
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net890.42
Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Sale Of Potential Future Royalties Net Of Transaction Costs-
Repayment Of Proceeds From Sale Of Future Royalties Net Of Transaction Costs-
Proceeds From Sale Of Future Royalties Net-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents15.12
Proceeds From Sale Of Future Royalties-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities894.12
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-120.18
Total Cash Flow24.15
4 historic quarters locked

Sign in to unlock the full Nektar Therapeutics cash flow history.

Sign In Create Free Account

About Nektar Therapeutics Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-349805

Figures are derived from filed reports and may be restated. Historical data is subject to revision.